Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free AYTU Stock Alerts

Aytu BioPharma (AYTU) Competitors

Aytu BioPharma logo
$2.57 +0.02 (+0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$2.59 +0.02 (+0.78%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AYTU vs. ALTS, COYA, ETHZ, NRXP, and ANIX

Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include ALT5 Sigma (ALTS), Coya Therapeutics (COYA), Flag Ship Acquisition (ETHZ), NRx Pharmaceuticals (NRXP), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry.

How does Aytu BioPharma compare to ALT5 Sigma?

ALT5 Sigma (NASDAQ:AIFC) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

In the previous week, ALT5 Sigma had 3 more articles in the media than Aytu BioPharma. MarketBeat recorded 5 mentions for ALT5 Sigma and 2 mentions for Aytu BioPharma. ALT5 Sigma's average media sentiment score of 0.11 beat Aytu BioPharma's score of 0.00 indicating that ALT5 Sigma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALT5 Sigma
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aytu BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Aytu BioPharma has a net margin of -39.02% compared to ALT5 Sigma's net margin of -1,386.90%. Aytu BioPharma's return on equity of -28.22% beat ALT5 Sigma's return on equity.

Company Net Margins Return on Equity Return on Assets
ALT5 Sigma-1,386.90% -50.52% -45.05%
Aytu BioPharma -39.02%-28.22%-5.20%

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aytu BioPharma has higher revenue and earnings than ALT5 Sigma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALT5 Sigma$24.84M4.20-$344.51MN/AN/A
Aytu BioPharma$62.64M0.44-$13.56M-$3.84N/A

ALT5 Sigma has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Aytu BioPharma has a consensus target price of $9.33, suggesting a potential upside of 263.16%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than ALT5 Sigma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALT5 Sigma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aytu BioPharma
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Aytu BioPharma beats ALT5 Sigma on 10 of the 14 factors compared between the two stocks.

How does Aytu BioPharma compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Coya Therapeutics currently has a consensus target price of $16.00, indicating a potential upside of 276.47%. Aytu BioPharma has a consensus target price of $9.33, indicating a potential upside of 263.16%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Coya Therapeutics is more favorable than Aytu BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Aytu BioPharma
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Aytu BioPharma had 1 more articles in the media than Coya Therapeutics. MarketBeat recorded 2 mentions for Aytu BioPharma and 1 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Coya Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aytu BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Coya Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.

Aytu BioPharma has a net margin of -39.02% compared to Coya Therapeutics' net margin of -267.13%. Aytu BioPharma's return on equity of -28.22% beat Coya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coya Therapeutics-267.13% -62.76% -53.84%
Aytu BioPharma -39.02%-28.22%-5.20%

Aytu BioPharma has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coya Therapeutics$7.95M12.54-$21.23M-$1.27N/A
Aytu BioPharma$62.64M0.44-$13.56M-$3.84N/A

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Coya Therapeutics beats Aytu BioPharma on 8 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to Flag Ship Acquisition?

Aytu BioPharma (NASDAQ:AYTU) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

Flag Ship Acquisition has lower revenue, but higher earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aytu BioPharma$62.64M0.44-$13.56M-$3.84N/A
Flag Ship Acquisition$4.11M25.39-$6.17M-$159.65N/A

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Aytu BioPharma had 2 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 2 mentions for Aytu BioPharma and 0 mentions for Flag Ship Acquisition. Aytu BioPharma's average media sentiment score of 0.00 equaled Flag Ship Acquisition'saverage media sentiment score.

Company Overall Sentiment
Aytu BioPharma Neutral
Flag Ship Acquisition Neutral

Flag Ship Acquisition has a net margin of 0.00% compared to Aytu BioPharma's net margin of -39.02%. Aytu BioPharma's return on equity of -28.22% beat Flag Ship Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Aytu BioPharma-39.02% -28.22% -5.20%
Flag Ship Acquisition N/A -185.71%-83.12%

Aytu BioPharma presently has a consensus target price of $9.33, indicating a potential upside of 263.16%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, research analysts clearly believe Aytu BioPharma is more favorable than Flag Ship Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu BioPharma
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Flag Ship Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Aytu BioPharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Flag Ship Acquisition has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.

Summary

Aytu BioPharma beats Flag Ship Acquisition on 9 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to NRx Pharmaceuticals?

Aytu BioPharma (NASDAQ:AYTU) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Aytu BioPharma currently has a consensus target price of $9.33, suggesting a potential upside of 263.16%. NRx Pharmaceuticals has a consensus target price of $38.25, suggesting a potential upside of 1,158.22%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Aytu BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu BioPharma
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Aytu BioPharma has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aytu BioPharma$62.64M0.44-$13.56M-$3.84N/A
NRx Pharmaceuticals$1.23M81.73-$28.62M-$1.39N/A

In the previous week, NRx Pharmaceuticals had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 2 mentions for Aytu BioPharma. NRx Pharmaceuticals' average media sentiment score of 1.54 beat Aytu BioPharma's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aytu BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NRx Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aytu BioPharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.

NRx Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -39.02%. NRx Pharmaceuticals' return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Aytu BioPharma-39.02% -28.22% -5.20%
NRx Pharmaceuticals N/A N/A -265.03%

Summary

NRx Pharmaceuticals beats Aytu BioPharma on 11 of the 16 factors compared between the two stocks.

How does Aytu BioPharma compare to Anixa Biosciences?

Aytu BioPharma (NASDAQ:AYTU) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

In the previous week, Anixa Biosciences had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for Aytu BioPharma. Anixa Biosciences' average media sentiment score of 0.34 beat Aytu BioPharma's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aytu BioPharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Anixa Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Anixa Biosciences has a net margin of 0.00% compared to Aytu BioPharma's net margin of -39.02%. Aytu BioPharma's return on equity of -28.22% beat Anixa Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aytu BioPharma-39.02% -28.22% -5.20%
Anixa Biosciences N/A -70.95%-62.53%

Anixa Biosciences has lower revenue, but higher earnings than Aytu BioPharma. Anixa Biosciences is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aytu BioPharma$62.64M0.44-$13.56M-$3.84N/A
Anixa BiosciencesN/AN/A-$10.93M-$0.33N/A

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aytu BioPharma presently has a consensus target price of $9.33, suggesting a potential upside of 263.16%. Anixa Biosciences has a consensus target price of $8.50, suggesting a potential upside of 183.33%. Given Aytu BioPharma's higher probable upside, research analysts clearly believe Aytu BioPharma is more favorable than Anixa Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aytu BioPharma
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20
Anixa Biosciences
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Aytu BioPharma has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Summary

Anixa Biosciences beats Aytu BioPharma on 8 of the 15 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AYTU vs. The Competition

Export
MetricAytu BioPharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$27.58M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-0.6738.8529.0428.47
Price / Sales0.44155.53476.6160.94
Price / Cash6.9557.8827.6236.52
Price / Book1.227.039.676.67
Net Income-$13.56M$23.62M$3.55B$332.53M
7 Day Performance0.78%3.67%1.70%2.01%
1 Month Performance-4.10%7.16%5.62%9.20%
1 Year Performance97.69%67.03%34.42%39.59%

Aytu BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AYTU
Aytu BioPharma
1.7665 of 5 stars		$2.57
+0.8%		$9.33
+263.2%		N/A$27.58M$62.64MN/A160
ALTS
ALT5 Sigma
N/A$0.86
+0.6%		N/AN/A$108.02M$24.84MN/A170
COYA
Coya Therapeutics
1.9393 of 5 stars		$4.26
-3.2%		$16.00
+275.6%		N/A$103.21M$7.95MN/A6
ETHZ
Flag Ship Acquisition
N/A$5.42
+11.3%		N/AN/A$103.05M$4.11MN/A7
NRXP
NRx Pharmaceuticals
3.6547 of 5 stars		$2.95
-2.6%		$38.25
+1,196.6%		N/A$100.19M$1.23MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AYTU) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel